Investor Overview Press Releases June 17, 2019 Aclaris Therapeutics Announces Positive 6-Month Results from a Phase 2 Open-Label Clinical Trial of ATI-502 Topical in Patients with Androgenetic Alopecia (Male/Female Pattern-Baldness) June 14, 2019 Aclaris Therapeutics to Present at the 2019 JMP Securities Life Sciences Conference May 24, 2019 Aclaris Therapeutics to Present at Jefferies 2019 Global Healthcare Conference View all » Events Jun 20, 201911:30 AM EDT Aclaris Therapeutics, Inc. at 2019 JMP Securities Life Sciences Conference Jun 17, 20198:00 AM EDT Aclaris Presents 6-Month Results From Androgenetic Alopecia Study Jun 5, 20193:30 PM EDT Aclaris Therapeutics, Inc. at Jefferies 2019 Global Healthcare Conference View all » Feature presentation Aclaris Therapeutics Company Overview
June 17, 2019 Aclaris Therapeutics Announces Positive 6-Month Results from a Phase 2 Open-Label Clinical Trial of ATI-502 Topical in Patients with Androgenetic Alopecia (Male/Female Pattern-Baldness)
